NeonMind Biosciences Inc (LCR) AI Stock Analysis

• Market Cap: C$3.24M
• Dividend Yield: N/A
• Average Volume (3M): 290.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: 2.62%
• Country: CA
• Employees: 28
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Industrial Materials
• EPS (TTM): >-0.01
• Shares Outstanding: 92,499,870
• 10 Day Avg. Volume: 583,757
• 30 Day Avg. Volume: 290,695
• PEG Ratio: 0.45
• Price to Book (P/B): -9.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.03 ▼(-17.50% Downside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is primarily constrained by very weak financial performance (no revenue, recurring losses, negative equity, and ongoing cash burn). Technicals add further pressure with the price below key moving averages and a negative MACD. Valuation provides limited support given a loss-driven negative P/E and no dividend yield data.

Positive Factors

Reduced cash burn (year-over-year)

A material reduction in operating cash outflow versus the prior year indicates management has begun to slow the rate of cash consumption. That durable trend lengthens runway, lowers near-term financing urgency, and improves the company's ability to execute next-stage R&D or commercialization plans without immediate large capital raises.

Shrinking historical losses

Reported losses have narrowed from prior peak years, suggesting improving cost control or lower extraordinary expenses. A persistent decline in absolute losses, if sustained, reduces cumulative deficit growth, eases pressure on working capital, and increases the odds management can reach break-even once revenue begins.

Lean operating structure (small team)

A compact employee base implies lower fixed overhead and potentially greater capital efficiency for a pre-revenue developer. Over the medium term this lean structure can preserve cash, enable nimble product pivots, and allow incremental scaling tied to milestone-driven funding or revenue inflection without a large step-up in fixed costs.

Negative Factors

Pre-revenue business model

No trailing revenue means the company has not demonstrated commercial product-market fit; operating losses and R&D spend remain dependent on future financing. This structural absence of revenue makes cash runway, product regulatory success, or partner deals the primary value drivers and increases execution risk over the medium term.

Negative shareholders' equity

Negative equity and debt roughly matching or exceeding assets signal a strained capital structure and elevated solvency risk. This limits access to traditional financing, increases the likelihood of dilutive capital raises, and constrains strategic flexibility for investments or partnerships over the coming months.

Persistently negative cash generation

Sustained negative operating and free cash flow indicate ongoing cash burn that must be met with external funding. Even with year-over-year improvement, nearly -1.0M TTM outflow is large relative to the balance sheet and creates recurring financing need, raising dilution and execution risk until positive cash generation is achieved.

NeonMind Biosciences Inc Business Overview & Revenue Model

Company Description

Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.

How the Company Makes Money

null

NeonMind Biosciences Inc Financial Statement Overview

Summary

Very weak fundamentals: the company is pre-revenue with persistent operating losses, negative shareholders’ equity, and ongoing cash burn (negative operating and free cash flow), implying continued reliance on external financing and elevated solvency risk.

Income Statement

The business is currently pre-revenue in the most recent periods (including TTM (Trailing-Twelve-Months) revenue of 0), with persistent operating losses (TTM EBIT of about -1.33M and net loss of about -1.75M). Profitability is structurally weak and has not yet demonstrated an ability to scale revenues to cover the cost base. A modest positive is that losses are smaller than the very large loss reported in 2021, but the overall earnings profile remains highly negative and unstable due to the absence of meaningful revenue.

Balance Sheet

The balance sheet is stressed by negative shareholders’ equity in the most recent periods (TTM equity about -0.64M), which limits financial flexibility and raises solvency risk. Debt remains meaningful relative to the asset base (TTM debt about 1.14M vs. assets about 1.09M), and the negative equity makes leverage indicators difficult to interpret but directionally concerning. The only clear improvement is versus 2025 annual where assets were very low, but overall capitalization remains weak and dependent on external funding.

Cash Flow

Cash generation is consistently negative, with TTM (Trailing-Twelve-Months) operating cash flow around -0.99M and free cash flow around -0.99M, indicating ongoing cash burn to fund operations. A relative strength is that cash burn improved materially versus 2024 (operating cash flow moved from roughly -1.13M to about -0.99M), but free cash flow remains negative across all shown periods, implying continued need for financing and limited near-term self-funding capacity.

Breakdown	Jun 2025	Jun 2024	Mar 2024	Feb 2023	Feb 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-1.58M	-897.00	―	-1.75M	-7.83M
Net Income	-1.75M	-1.54M	―	-2.03M	-7.21M
Balance Sheet
Total Assets	1.09M	91.12K	719.33K	129.43K	1.34M
Cash, Cash Equivalents and Short-Term Investments	206.03K	13.98K	135.40K	69.91K	967.27K
Total Debt	1.14M	1.19M	1.04M	846.94K	450.01K
Total Liabilities	1.74M	2.00M	1.33M	1.53M	1.05M
Stockholders Equity	-635.18K	-1.90M	-612.89K	-1.40M	290.30K
Cash Flow
Free Cash Flow	-988.65K	-89.79K	-1.31M	-1.22M	-5.82M
Operating Cash Flow	-988.66K	-89.79K	-1.13M	-1.08M	-5.82M
Investing Cash Flow	-129.42K	37.60K	-36.15K	72.14K	389.12K
Financing Cash Flow	1.29M	0.00	627.93K	271.00K	6.20M

NeonMind Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.04 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LCR.

NeonMind Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
LEXT	43 Neutral	C$1.76M	-2.69	-293.33%	―	―	28.37%
LCR	41 Neutral	C$3.24M	-4.61	150.31%	―	―	2.62%

NeonMind Biosciences Inc Corporate Events

Lancaster Resources Refreshes Board as It Sharpens Exploration Focus

Lancaster Resources Inc. has announced that director Penny White resigned from the board on March 3, 2026, with the company expressing appreciation for her contributions. At the same time, the miner appointed geologist Rob Heaslop to its board of directors, effective immediately, as it reshapes its leadership.

Heaslop brings two decades of exploration and resource development experience across Africa, Australia, and the Pacific, along with a track record in project generation for precious and base metals. His appointment is intended to support Lancaster’s new strategic direction and strengthen technical oversight as it advances the Lake Cargelligo gold project, the Lac Iris polymetallic asset, and other critical and precious mineral properties to drive growth and shareholder value.

The most recent analyst rating on (TSE:LCR) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on NeonMind Biosciences Inc stock, see the TSE:LCR Stock Forecast page.

Lancaster Resources Launches Phase 1 Exploration Program at Lake Cargelligo Gold-Silver Project

Lancaster Resources Inc. has outlined its 2026 Phase 1 Exploration and Project Development Program for the Lake Cargelligo Project in New South Wales, designed to advance the site’s district-scale gold and silver potential while also assessing tin and tungsten targets. The work plan includes expanded geological mapping and surface sampling, ground and airborne geophysical surveys, and a roughly 2,500-metre drilling campaign at the Josephine Moulder target to test historical high-grade results and refine resource modelling. By compiling extensive historical assay data, pursuing new drilling and geophysics, and initiating permitting and landowner consultations, Lancaster aims to accelerate its understanding of the scale and grade of mineralization and evaluate potential processing synergies with nearby operating mines, positioning the project for future resource definition and possible faster path to cash flow.